The estimated Net Worth of Jay Lichter is at least $22.4 Million dollars as of 26 February 2021. Jay Lichter owns over 893,828 units of Otonomy Inc stock worth over $8,773 and over the last 11 years he sold OTIC stock worth over $22,300,414. In addition, he makes $91,511 as Independent Chairman of the Board at Otonomy Inc.
Sign up
Jay Lichter OTIC stock SEC Form 4 insiders trading
Jay has made over 7 trades of the Otonomy Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 321,180 units of OTIC stock worth $867,186 on 3 March 2021.
The largest trade he's ever made was selling 1,082,353 units of Otonomy Inc stock on 23 February 2021 worth over $3,192,941. On average, Jay trades about 170,359 units every 112 days since 2013. As of 26 February 2021 he still owns at least 113,935 units of Otonomy Inc stock.
You can see the complete history of Jay Lichter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jay Lichter biography
Dr. Jay B. Lichter Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Lichter served as our Chief Executive Officer from inception until November 2010. Dr. Lichter is currently chief executive officer of Avelas BioSciences and Fortis, both private biotechnology companies. He is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early-stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon’s investments in public companies SynthoRx, Inc. and Aratana Therepeutics, Inc., and served as a director and chief executive officer for several privately-held biotechnology companies. He previously served on the board of directors of Aratana Therapeutics, Inc., a public pharmaceutical company, from December 2010 to August 2015, and currently serves on the board of directors of SynthoRx, Inc., a biotechnology company. Dr. Lichter also led Avalon’s investments in or currently serves on the board of several privately-held companies, including AristaMD, Fortis Therapeutics, Inc., Avelas BioSciences, Inc., COI Pharmaceuticals Inc., Sitari Pharmaceuticals Corp. and Sova Pharmaceuticals, Inc., among other life science companies. Dr. Lichter received a Bachelor’s degree and Ph.D. in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.
What is the salary of Jay Lichter?
As the Independent Chairman of the Board of Otonomy Inc, the total compensation of Jay Lichter at Otonomy Inc is $91,511. There are 6 executives at Otonomy Inc getting paid more, with David Weber having the highest compensation of $2,153,120.
How old is Jay Lichter?
Jay Lichter is 58, he's been the Independent Chairman of the Board of Otonomy Inc since 2015. There are 7 older and 4 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.
What's Jay Lichter's mailing address?
Jay's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.
Insiders trading at Otonomy Inc
Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo, and Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.
What does Otonomy Inc do?
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
What does Otonomy Inc's logo look like?
Complete history of Jay Lichter stock trades at Otonomy Inc
Otonomy Inc executives and stock owners
Otonomy Inc executives and other stock owners filed with the SEC include:
-
David Weber,
President, Chief Executive Officer, Director -
Dr. David Allen Weber,
Pres, CEO & Director -
Paul Cayer,
Chief Financial and Business Officer -
Robert Savel,
Chief Technical Officer -
Paul E. Cayer,
Chief Financial & Bus. Officer -
Robert Michael Savel II,
Chief Technical Officer -
Jay Lichter,
Independent Chairman of the Board -
Vickie Capps,
Independent Director -
Iain McGill,
Independent Director -
James Breitmeyer,
Independent Director -
Theodore Schroeder,
Independent Director -
Dr. Jay B. Lichter Ph.D.,
Co-Founder & Independent Chairman -
Ciara Kennedy,
Independent Director -
James Branch CPA,
VP of Fin. & Controller -
David Skarinsky,
Sr. VP of Clinical -
Breianna Bowen,
VP of HR -
Fabrice Piu Ph.D.,
Sr. VP of Preclinical Devel. -
Barbara M. Finn,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Alan Charles Foster Ph.D.,
Chief Scientific Officer -
Julie D. Burgess,
VP of Fin. & Admin. -
Dr. Rick Adam Friedman M.D., Ph.D.,
Co-Founder and Member of the Advisory Panel -
Dr. Allen F. Ryan Ph.D.,
Co-Founder and Member of the Advisory Panel -
Katherine Mary Bishop,
Chief Scientific Officer -
Eric J Loumeau,
GC & Chief Compliance Officer -
Carl Le Bel,
Chief Scientific Officer -
Heather Preston,
Director -
George J Morrow,
Director -
Advisors Llc Orbi Med Capit...,
-
Chau Quang Khuong,
Director -
Anthony J Yost,
Chief Commercial Officer -
Dean Hakanson,
Chief Medical Officer -
John P Mckearn,
Director -
Partners Viii, L.P.Blair Ja...,
-
Ventures Viii Lp Avalon Ven...,
-
Holdings A/S Novo,
10% owner -
Group Holdings (Sbs) Adviso...,
-
Viii Associates, L.P.Domain...,
-
Alan Charles Foster,
Chief Scientific Officer -
Brian H Dovey,
Director -
Jill Marie Broadfoot,
Director